Ambria Capital
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Ambria Capital.
Key people at Ambria Capital.
Ambria Capital is a venture capital firm focused on empowering early-stage companies primarily in the mental health and technology sectors, with a strong emphasis on psychedelics, digital health, cryptocurrency, and cybersecurity. Their mission centers on supporting entrepreneurs who aim to transform markets and improve millions of lives by addressing pressing challenges in mental health and frontier technologies. The firm takes a hands-on, long-term approach by investing its own capital and making independent decisions to back visionary founders and innovative solutions[1][2].
Founded in 2018 by Michael Sobeck, an advocate for psychedelic medicine and founder of the Perception Restoration Foundation, Ambria Capital has evolved to become a leading investor in the emerging psychedelics space. Sobeck’s background in mental health and his commitment to advancing psychedelic-assisted therapies have shaped the firm’s focus on companies that are pioneering new treatments for mental health disorders. The firm is headquartered in San Juan, Puerto Rico, and has invested in over 20 companies, including notable names like atai and Small Pharma[3][4].
Ambria Capital is riding the wave of a mental health revolution driven by scientific breakthroughs in psychedelics and digital therapeutics. The firm’s timing is critical as psychedelics gain FDA breakthrough designations, regulatory momentum, and growing public acceptance. This convergence creates a massive market opportunity to address the global mental health crisis, where traditional treatments have fallen short. By backing companies at the forefront of this shift, Ambria influences the broader ecosystem by accelerating innovation, shaping regulatory frameworks, and fostering a new generation of mental health solutions[2][4].
Looking ahead, Ambria Capital is poised to deepen its impact as psychedelic-assisted therapies move closer to mainstream adoption and as digital health technologies continue to expand. Trends such as increased regulatory approvals, growing capital inflows, and evolving public sentiment will shape their investment journey. The firm’s continued focus on early-stage, high-impact companies suggests it will remain a key player in transforming mental health care and frontier technology sectors, potentially expanding its portfolio and influence globally[2][4].
In summary, Ambria Capital stands out as a mission-driven venture firm uniquely positioned at the intersection of mental health innovation and emerging technologies, committed to long-term value creation and societal impact.
Key people at Ambria Capital.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2022 | HealingMaps | $1.0M Seed | — | Jenny Friedman, XEIA Venture Partners, Vinay Hiremath |
| Sep 1, 2021 | incident.io | $6.0M Seed | — | Alt Capital, Crane Venture Partners, Eka Ventures, Felix Capital, Founders Fund, General Catalyst, Hanabi Capital, Index Ventures, Jenny Friedman, MMC Ventures, Saga, ShareBear Capital, Starship Ventures, XEIA Venture Partners, Adam Guild, Dylan Field, Sam Altman, Shane Curran |
| Apr 1, 2021 | Semasio | $30.0M Series B | — | — |
